REGENERON PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Directors: N. Anthony Coles, M.D.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: N. Anthony Coles, M.D.”): 110,481,731 for, 1,873,397 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: The following nominee for Class II director was elected to …”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 192 asset managers below reported 48,111,232 for, 642,137 against, 20,644 abstained.

Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.

Description as filed by funds: Election of Directors: Kathryn Guarini, Ph.D.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kathryn Guarini, Ph.D.”): 111,988,738 for, 359,659 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: The following nominee for Class II director was elected to …”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 192 asset managers below reported 48,753,352 for, 15 against, 20,644 abstained.

Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.

Description as filed by funds: Election of Directors: Arthur F. Ryan

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Arthur F. Ryan”): 81,009,658 for, 31,288,101 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: The following nominee for Class II director was elected to …”
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 192 asset managers below reported 39,077,581 for, 9,675,784 against, 20,647 abstained.

Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.

Description as filed by funds: Election of Directors: David P. Schenkein, M.D.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David P. Schenkein, M.D.”): 106,839,998 for, 5,501,139 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: The following nominee for Class II director was elected to …”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 192 asset managers below reported 47,921,465 for, 831,903 against, 20,644 abstained.

Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.

Description as filed by funds: Election of Directors: George L. Sing

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: George L. Sing”): 102,751,205 for, 9,574,839 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: The following nominee for Class II director was elected to …”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 192 asset managers below reported 46,955,329 for, 1,798,041 against, 20,643 abstained.

Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.

Description as filed by funds: Proposal to approve, on an advisory basis, executive compensation.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule ”): 106,667,264 for, 5,579,814 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 25, 2024 was approved based on the following votes:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 184 managers: 48,747,717 for, 13,891 against, 20,651 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 839 managers: 66,017,103 for, 3,969,645 against, 2 withheld, 131 abstained, 4,023 not voted, 224 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the ”): 111,350,016 for, 5,257,636 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved based upon the fol…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 193 asset managers below reported 48,645,248 for, 116,596 against, 20,641 abstained.

Showing the 25 largest of 193 asset managers. See all 193 in the interactive database.

Description as filed by funds: Non-binding shareholder proposal requesting simple majority voting requirements, if properly presented.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“4. Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements The non-binding shareholder proposal requesting simple majority voting requirements”): 85,900,254 for, 26,365,621 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 – Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements The non-binding shareholder proposal requesting simple majority voting requirements was approved based upon the following votes:”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of REGENERON PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Adopt Simple Majority Vote” (8 managers, 3,414,727 for, 280 abstained).

The 188 asset managers below reported 44,615,434 for, 723,206 against, 20,365 abstained.

Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.